Mankind Pharma Ltd

Mankind Pharma Ltd has witnessed a significant 26.3% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a strong intraday performance and outperformance relative to its sector, the stock faces mixed technical indicators and a recent downgrade in its mojo rating, prompting a nuanced outlook for traders and investors alike.

Mankind Pharma Ltd (MANKIND) witnessed a significant 17.5% increase in open interest in its derivatives segment on 3 Feb 2026, signalling heightened market interest and potential directional bets. The stock outperformed its sector and broader indices, supported by a notable volume surge and positive price action, despite mixed moving average signals and declining delivery volumes.

Mankind Pharma Ltd demonstrated robust intraday performance on 3 Feb 2026, surging to an intraday high of Rs 2,152.5, marking a 4.13% increase from the previous close. The stock outpaced its sector and broader market indices, reflecting notable trading momentum amid a mixed market backdrop.

Mankind Pharma Ltd’s shares declined to a fresh 52-week low of Rs.2053 today, marking a significant milestone in the stock’s recent performance. This new low reflects ongoing pressures on the company’s valuation amid subdued profit growth and valuation concerns within the Pharmaceuticals & Biotechnology sector.

Mankind Pharma Ltd has witnessed a notable 10.75% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock trading near its 52-week low. This surge in open interest, coupled with volume patterns and price movements, offers insights into evolving market positioning and potential directional bets among investors.

Mankind Pharma Ltd’s shares declined to a fresh 52-week low of Rs.2060 on 27 Jan 2026, marking a significant price level amid a broader market downturn. The stock has underperformed its sector and key indices, reflecting a combination of subdued financial results and valuation concerns.

Mankind Pharma Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Mankind Pharma Ltd has witnessed a notable 11.23% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading near its 52-week low, the stock’s volume and open interest dynamics suggest a complex interplay of directional bets amid a cautious sector backdrop.

Mankind Pharma Ltd’s shares declined to a fresh 52-week low of Rs.2087.55 today, marking a significant downturn amid broader market fluctuations and company-specific performance factors. The stock has now recorded a three-day consecutive fall, losing 5.73% over this period, while underperforming its sector and the broader Sensex index over the past year.

Mankind Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating moving averages and mixed oscillator readings, suggests increasing downside pressure amid a challenging market backdrop.

Mankind Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bearish to a bearish trend. The company’s recent downgrade from a Hold to a Sell rating by MarketsMOJO, accompanied by a Mojo Score of 38.0, reflects growing concerns over its near-term price performance despite some bullish signals on shorter timeframes.

Mankind Pharma Ltd has witnessed a significant 20.5% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor sentiment. This increase accompanies a robust volume uptick and a notable outperformance against its sector, suggesting evolving directional bets and positioning among traders.

Mankind Pharma Ltd demonstrated robust intraday strength on 7 Jan 2026, surging to an intraday high of Rs 2,320.35, marking a 3.5% increase from its previous close. This performance notably outpaced the broader Sensex, which traded lower by 0.31% during the session.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. The pharmaceutical giant’s stock outperformed its sector peers, buoyed by increased volumes and a notable uptick in delivery volumes, reflecting growing investor confidence despite a recent downgrade in its Mojo Grade.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The pharmaceutical giant’s stock outperformed its sector and broader indices, supported by rising volumes and delivery volumes, reflecting growing investor confidence despite a recent downgrade in its Mojo Grade to Sell.